Literature DB >> 8636587

The effects of antihypertensive treatment on cognitive function: results from the HOPE study.

J M Starr1, L J Whalley, I J Deary.   

Abstract

OBJECTIVES: Hypertension is associated with impaired cognition, but it is unclear whether this impairment is reversible. We sought to evaluate the effect of blood pressure reduction on cognition.
DESIGN: A randomized, double-blind trial.
SETTING: A single center, with assessments in subjects' domiciles. PARTICIPANTS: Community-screened subjects more than 69 years of age who had median diastolic pressures > 99 mm Hg and systolic pressures > 159 mm Hg or diastolic > 85 mm Hg and systolic > 179 mm Hg with Mini-Mental State Examination scores of 20 to 28. Subjects had not previously received antihypertensive treatment. INTERVENTION: Captopril 12.5 mg twice daily or bendrofluazide 2.5 mg daily for 24 weeks, preceded by a 2-week placebo phase. MEASUREMENTS: Cognition was evaluated by a psychometric test battery comprising Immediate and Delayed Logical Memory, Paired Associates recall, Raven's Progressive Matrices, Halstead Reitan Trail Making A, and the Anomalous Sentences Repetition Test.
RESULTS: Eighty-one subjects (28 male, 53 female) were treated (41 captopril, 40 bendrofluazide). At entry, mean age was 76.1 years (range 70-84), mean blood pressure was 191 (160-230) mm Hg systolic, 101 (88-110) mm Hg diastolic, and mean MMSE score 26.1. A total of 69 subjects completed the trial. The 25th, 50th, and 75th percentiles of the difference between pretreatment and Week 24 blood pressures wer 15 mm Hg, 35 mm Hg, and 50 mm Hg (systolic) and 5 mm Hg, 10 mm Hg, and 19 mm Hg (diastolic). There were no significant differences in any psychometric test between captopril and bendrofluazide. The 19 subjects in the quartile that lowered their diastolic blood pressure most ( > or = 19 mm Hg) had improved scores on Anomalous Sentences (P = .012) and Paired Associates (P = .044) compared to the 19 subjects in the least blood pressure responsive quartile (fall < or = 5 mm Hg)s.
CONCLUSION: The treatment of hypertension is not hazardous to cognitive function in older people with pre-existing cognitive impairment. Long-term adequate blood pressure control may reverse cognitive impairment associated with pre-existing hypertension.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636587     DOI: 10.1111/j.1532-5415.1996.tb06412.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  24 in total

Review 1.  Hypertension and dementia.

Authors:  A S Rigaud; O Hanon; M L Seux; F Forette
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 2.  Does the angiotensin II receptor antagonist losartan improve cognitive function?

Authors:  Michele A Tedesco; Gennaro Ratti; Giovanni Di Salvo; Francesco Natale
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

Review 4.  Drug-induced cognition disorders in the elderly: incidence, prevention and management.

Authors:  S L Gray; K V Lai; E B Larson
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

Review 5.  Antihypertensive Therapies and Cognitive Function: a Review.

Authors:  Nisharahmed Kherada; Todd Heimowitz; Clive Rosendorff
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

Review 6.  Clinical Trials of Blood Pressure Lowering and Antihypertensive Medication: Is Cognitive Measurement State-of-the-Art?

Authors:  Merrill F Elias; Rachael V Torres; Adam Davey
Journal:  Am J Hypertens       Date:  2018-05-07       Impact factor: 2.689

Review 7.  [Alzheimer Disease].

Authors:  Fadi Massoud
Journal:  Can Fam Physician       Date:  2007-01       Impact factor: 3.275

Review 8.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia.

Authors:  Howard Chertkow; Fadi Massoud; Ziad Nasreddine; Sylvie Belleville; Yves Joanette; Christian Bocti; Valérie Drolet; John Kirk; Morris Freedman; Howard Bergman
Journal:  CMAJ       Date:  2008-05-06       Impact factor: 8.262

10.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.